Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial

Eitan Kerem, Michael W. Konstan, Kris De Boeck, Frank J. Accurso, Isabelle Sermet-Gaudelus, Michael Wilschanski, J. Stuart Elborn, Paola Melotti, Inez Bronsveld, Isabelle Fajac, Anne Malfroot, Daniel B. Rosenbluth, Patricia A. Walker, Susanna A. McColley, Christiane Knoop, Serena Quattrucci, Ernst Rietschel, Pamela L. Zeitlin, Jay Barth, Gary L. ElfringEllen M. Welch, Arthur Branstrom, Robert J. Spiegel, Stuart W. Peltz, Temitayo Ajayi, Steven M. Rowe

Research output: Contribution to journalArticlepeer-review

296 Scopus citations

Fingerprint

Dive into the research topics of 'Ataluren for the treatment of nonsense-mutation cystic fibrosis: A randomised, double-blind, placebo-controlled phase 3 trial'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology

Pharmacology, Toxicology and Pharmaceutical Science